Vertex Net Income Per Share from 2010 to 2024

VRTX Stock  USD 465.73  2.40  0.51%   
Vertex Pharmaceuticals Net Income Per Share yearly trend continues to be fairly stable with very little volatility. Net Income Per Share is likely to outpace its year average in 2024. During the period from 2010 to 2024, Vertex Pharmaceuticals Net Income Per Share regression line of annual values had r-squared of  0.80 and arithmetic mean of  4.44. View All Fundamentals
 
Net Income Per Share  
First Reported
2010-12-31
Previous Quarter
14.04578968
Current Value
14.75
Quarterly Volatility
6.48574226
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vertex Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vertex Pharmaceuticals' main balance sheet or income statement drivers, such as Total Revenue of 10.4 B, Gross Profit of 9 B or Other Operating Expenses of 6.3 B, as well as many indicators such as Price To Sales Ratio of 10.09, Dividend Yield of 0.0 or PTB Ratio of 7.46. Vertex financial statements analysis is a perfect complement when working with Vertex Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Vertex Pharmaceuticals Correlation against competitors.
For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Latest Vertex Pharmaceuticals' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Vertex Pharmaceuticals over the last few years. It is Vertex Pharmaceuticals' Net Income Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vertex Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Vertex Net Income Per Share Regression Statistics

Arithmetic Mean4.44
Geometric Mean2.59
Coefficient Of Variation146.10
Mean Deviation5.74
Median1.06
Standard Deviation6.49
Sample Variance42.06
Range17.8939
R-Value0.90
Mean Square Error8.93
R-Squared0.80
Slope1.30
Total Sum of Squares588.91

Vertex Net Income Per Share History

2024 14.75
2023 14.05
2022 12.97
2021 9.09
2020 10.44
2019 4.58
2018 8.25

About Vertex Pharmaceuticals Financial Statements

Vertex Pharmaceuticals investors use historical fundamental indicators, such as Vertex Pharmaceuticals' Net Income Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vertex Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income Per Share 14.05  14.75 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.